Effect of 1,25-(OH)2D3 on jejunal absorption of magnesium in patients with chronic renal disease

A. C. Schmulen, M. Lerman, C. Y C Pak

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

These studies were performed to see if jejunal malabsorption of magnesium in patients with chronic renal disease was influenced by therapy with 1α,25-dihydroxyvitamin D3 [1,25-(OH)2D3; 2 μg/day by mouth for 7 days]. This treatment restored normal serum concentrations of the vitamin D metabolite from 0.9 ± 0.2 to 4.2 ± 0.6 ng/dl. Jejunal absorption of magnesium, measured by a triple-lumen constant-perfusion technique, was enhanced in each of the seven patients by this therapy. The mean value rose from 0.04 ± 0.02 to 0.13 ± 0.02 mmol.30 cm-1.h-1. This last value is similar to the magnesium absorption rate in untreated normal subjects. These results demonstrate that magnesium absorption in the human jejunum is dependent on vitamin D, and they show that 1α,25-dihydroxyvitamin D3 therapy in patients with chronic renal failure is associated with an enhanced jejunal absorption of magnesium.

Original languageEnglish (US)
Pages (from-to)349-352
Number of pages4
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume1
Issue number4
StatePublished - Jan 1 1980

ASJC Scopus subject areas

  • Physiology
  • Hepatology
  • Gastroenterology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Effect of 1,25-(OH)<sub>2</sub>D<sub>3</sub> on jejunal absorption of magnesium in patients with chronic renal disease'. Together they form a unique fingerprint.

Cite this